Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report

Abstract Background The BRCA2 gene is a well-known tumor suppressor gene implicated in breast and ovarian cancers. BRCA1/2 mutations can be sensitive to poly ADP-ribose polymerase (PARP) inhibitors such as olaparib. However, some of these patients develop resistance to this treatment and an essentia...

Full description

Bibliographic Details
Main Authors: Auro del Giglio, Beatriz da Costa Aguiar Alves, André Márcio Murad, Fernando Luiz Affonso Fonseca
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Journal of Medical Case Reports
Subjects:
BRCA2
Reversion mutation
Therapy resistance
Online Access:https://doi.org/10.1186/s13256-023-04139-x

Internet

https://doi.org/10.1186/s13256-023-04139-x

Similar Items